Unknown

Dataset Information

0

Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer.


ABSTRACT: Despite improvements in surgery and medical treatments, epithelial ovarian cancer (EOC) remains the most lethal gynaecological malignancy. Aim of this study is to investigate the preclinical immunotherapy activity of cytokine-induced killer lymphocytes (CIK) against epithelial ovarian cancers, focusing on platinum-resistant settings. We generated CIK ex vivo starting from human peripheral blood samples (PBMCs) collected from EOC patients. Their antitumor activity was tested in vitro and in vivo against platinum-resistant patient-derived ovarian cancer cells (pdOVCs) and a Patient Derived Xenograft (PDX), respectively. CIK were efficiently generated (48 fold median ex vivo expansion) from EOC patients; pdOVCs lines (n?=?9) were successfully generated from metastatic ascites; the expression of CIK target molecules by pdOVC confirmed pre and post treatment in vitro with carboplatin. The results indicate that patient-derived CIK effectively killed autologous pdOVCs in vitro. Such intense activity was maintained against a subset of pdOVC that survived in vitro treatment with carboplatin. Moreover, CIK antitumor activity and tumor homing was confirmed in vivo within an EOC PDX model. Our preliminary data suggest that CIK are active in platinum resistant ovarian cancer models and should be therefore further investigated as a new therapeutic option in this extremely challenging setting.

SUBMITTER: Capellero S 

PROVIDER: S-EPMC7160190 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer.

Capellero S S   Erriquez J J   Melano C C   Mesiano G G   Genta S S   Pisacane A A   Mittica G G   Ghisoni E E   Olivero M M   Di Renzo M F MF   Aglietta M M   Sangiolo D D   Valabrega G G  

Scientific reports 20200415 1


Despite improvements in surgery and medical treatments, epithelial ovarian cancer (EOC) remains the most lethal gynaecological malignancy. Aim of this study is to investigate the preclinical immunotherapy activity of cytokine-induced killer lymphocytes (CIK) against epithelial ovarian cancers, focusing on platinum-resistant settings. We generated CIK ex vivo starting from human peripheral blood samples (PBMCs) collected from EOC patients. Their antitumor activity was tested in vitro and in vivo  ...[more]

Similar Datasets

| S-EPMC7189715 | biostudies-literature
| S-EPMC5498561 | biostudies-literature
| S-EPMC8642969 | biostudies-literature
| S-EPMC6430659 | biostudies-literature
| S-EPMC5840363 | biostudies-literature
| S-EPMC7764119 | biostudies-literature
| S-EPMC6115831 | biostudies-literature
| S-EPMC4869278 | biostudies-literature
| S-EPMC10768003 | biostudies-literature
| S-EPMC4429635 | biostudies-literature